Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study.
Interleukin-17 inhibitors (anti-IL17)
Ixekizumab (IXE)
Persistence
Psoriatic arthritis (PsA)
Real-world evidence (RWE)
Secukinumab (SECU)
Treatment patterns
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
28
07
2023
accepted:
22
09
2023
medline:
30
10
2023
pubmed:
7
10
2023
entrez:
7
10
2023
Statut:
ppublish
Résumé
Given the growing interest and use of interleukin-17 inhibitors (anti-IL17) for the treatment of psoriatic arthritis (PsA), an observational study has been conducted to characterize the patient profile, treatment patterns, and persistence of ixekizumab or secukinumab in patients with PsA receiving them as first anti-IL17. This is a multicenter retrospective study, conducted at eight Spanish hospitals where data from adult patients with PsA were collected from electronic medical records. Three cohorts of patients, initiating treatment with an anti-IL17 [secukinumab 150 mg (SECU150), secukinumab 300 mg (SECU300), or ixekizumab (IXE)] between January 2019 and March 2021, were included. Demographic and clinical patient characteristics, treatment patterns, and persistence were analyzed descriptively. Continuous data were presented as mean [standard deviation (SD)] and categorical variables as frequencies with percentages. Persistence rates at 3, 6, and 12 months were calculated. A total of 221 patients with PsA were included in the study [SECU150, 103 (46.6%); SECU300, 38 (17.2%); and IXE, 80 (36.2%)]. Treatment patterns differed by clinical characteristics: SECU150 was initiated more frequently in patients with moderate PsA and less peripheral joint involvement, while patients on SECU300 included those with a higher rate of enthesitis and active skin psoriasis, and patients on IXE showed a longer time since PsA diagnosis, more frequent comorbidities, joint involvement, and diagnosed skin psoriasis. Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) were previously administered in 88.2% of patients and biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) were administered in 72.9%. The mean number of previous b/tsDMARDs was 2.4 (SD 1.5) in the IXE cohort, 1.7 (SD 0.9) in the SECU300 cohort, and 1.6 (SD 1.0) for those in the SECU150 cohort. The global persistence on all anti-IL17 was 97.2%, 88.4%, and 81.0% at 3, 6, and 12 months, respectively. The most frequent reason for discontinuation across the three cohorts was lack of effectiveness (16.7%; 37/221). Most of the patients with PsA treated with anti-IL17 in Spain had moderate to severe disease activity, high peripheral joint and skin involvement, and had received previous b/tsDMARDs. More than 80% of patients with a 1-year follow-up persisted on anti-IL17, with the highest rate observed in the IXE cohort, followed by the SECU150 then SECU300 cohorts.
Identifiants
pubmed: 37804475
doi: 10.1007/s12325-023-02693-w
pii: 10.1007/s12325-023-02693-w
pmc: PMC10611868
doi:
Substances chimiques
Antirheumatic Agents
0
Types de publication
Observational Study
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
5415-5431Informations de copyright
© 2023. The Author(s).
Références
Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87.
doi: 10.1136/annrheumdis-2016-209709
pubmed: 27553214
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–70.
doi: 10.1056/NEJMra1505557
pubmed: 28273019
Fundación SER. Se ha presentado el Estudio EPISER 2016 en la sede del Ministerio de Sanidad, Consumo y Bienestar Social-SER. 2019. https://www.ser.es/se-ha-presentado-el-estudio-episer-2016-en-la-sede-del-ministerio-de-sanidad-consumo-y-bienestar-social/ . Accessed 29 Jan 2020.
Cabrera-Salom C, Motta Beltrán A, Medina Y. Presentación inusual de psoriasis ostrácea y artritis psoriásica: resultados después de 10 años de manejo con infliximab. Revis Colomb Reumatol. 2019. https://www.elsevier.es/es-revista-revista-colombiana-reumatologia-374-pdf-S0121812318300367 . Accessed 29 Jan 2020.
Coates L, Gossec L. The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences. Jt Bone Spine. 2023;90(1):105469.
doi: 10.1016/j.jbspin.2022.105469
Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–79.
doi: 10.1038/s41584-022-00798-0
pubmed: 35761070
pmcid: 9244095
Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–84.
doi: 10.1016/S0140-6736(18)30830-4
pubmed: 29893226
de Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol. 2014;94(6):627–34.
doi: 10.2340/00015555-1833
pubmed: 24573106
Torre Alonso JC, Del Campo D, Fontecha P, et al. Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis. Reumatol Clin (Engl Ed). 2018;14(5):254–68.
doi: 10.1016/j.reuma.2017.08.007
pubmed: 29111261
AEMPS. Informe de Posicionamiento Terapéutico de secukinumab (Cosentyx
EMA. Taltz Summary of Product Characteristics. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/taltz . Accessed 29 Jan 2020.
AEMPS. Informe de Posicionamiento Terapéutico de ixekizumab (Taltz
EMA. Cosentyx Summary of Product Characteristics. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx . Accessed 29 Jan 2020.
Novartis. Novartis receives approval for Cosentyx
McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–46.
doi: 10.1016/S0140-6736(15)61134-5
pubmed: 26135703
Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol. 2020;2(1):18–25.
doi: 10.1002/acr2.11097
pubmed: 31943974
McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496–505.
doi: 10.1016/S0140-6736(20)30564-X
pubmed: 32386593
McInnes IB, Mease PJ, Kivitz AJ, et al. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. Lancet Rheumatol. 2020;2(4):e227–35.
doi: 10.1016/S2665-9913(20)30036-9
Chandran V, van der Heijde D, Fleischmann RM, et al. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology (Oxford). 2020;59(10):2774–84.
doi: 10.1093/rheumatology/kez684
pubmed: 32031665
Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317–27.
doi: 10.1016/S0140-6736(17)31429-0
pubmed: 28551073
Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford). 2010;49(7):1367–73.
doi: 10.1093/rheumatology/keq102
pubmed: 20388640
Perrone V, Losi S, Filippi E, et al. Analysis of the pharmacoutilization of biological drugs in psoriatic arthritis patients: a real-world retrospective study among an Italian population. Rheumatol Ther. 2022;9(3):875–90.
doi: 10.1007/s40744-022-00440-1
pubmed: 35316515
pmcid: 9127009
Gladman DC, Choquette D, Khraishi M, et al. Real-world retention and clinical effectiveness of secukinumab for psoriatic arthritis: results from the CanSpA Research Network. J Rheumatol. 2023;50(5):641–8.
Reich A, Reed C, Schuster C, Robert C, Treuer T, Lubrano E. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021. J Dermatol Treat. 2023;34(1):2160196.
doi: 10.1080/09546634.2022.2160196
Braña I, Pardo E, Burger S, González del Pozo P, Alperi M, Queiro R. Treatment retention and safety of ixekizumab in psoriatic arthritis: a real life single-center experience. J Clin Med. 2023;12(2):467.
doi: 10.3390/jcm12020467
pubmed: 36675395
pmcid: 9861177
Moreno-Ramos MJ, Sanchez-Piedra C, Martínez-González O, et al. Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the Spanish BIOBADASER Registry. Rheumatol Ther. 2022;9(4):1031–47.
doi: 10.1007/s40744-022-00446-9
pubmed: 35467242
pmcid: 9314517
Michelsen B, Georgiadis S, Di Giuseppe D, et al. Real-world six- and twelve-month drug retention, remission, and response rates of secukinumab in 2,017 patients with psoriatic arthritis in thirteen European countries. Arthritis Care Res (Hoboken). 2022;74(7):1205–18.
doi: 10.1002/acr.24560
pubmed: 33460531
Perrotta FM, Delle Sedie A, Scriffignano S, et al. Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study. Reumatismo. 2020;72(1):52–9.
doi: 10.4081/reumatismo.2020.1266
pubmed: 32292021
Conaghan PG, Keininger DL, Holdsworth EA, et al. Real world effectiveness and satisfaction with secukinumab in the treatment of patients with psoriatic arthritis: a population survey in five European countries. Curr Med Res Opin. 2021;37(10):1845–53.
doi: 10.1080/03007995.2021.1954500
pubmed: 34256669
Ramonda R, Lorenzin M, Carriero A, et al. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open. 2021;7:1519.
doi: 10.1136/rmdopen-2020-001519
Manfreda V, Chimenti MS, Canofari C, et al. Efficacy and safety of Ixekizumab in psoriatic arthritis: a retrospective, single-centre, observational study in a real-life clinical setting. Clin Exp Rheumatol. 2020;38(3):581–2.
pubmed: 32105590
Valero-Expósito M, Martín-López M, Guillén-Astete C, et al. Retention rate of secukinumab in psoriatic arthritis: real-world data results from a Spanish multicenter cohort. Medicine (Baltimore). 2022;101(36): e30444.
doi: 10.1097/MD.0000000000030444
pubmed: 36086678
Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–12.
doi: 10.1136/annrheumdis-2020-217159
pubmed: 32434812
Joven B, Hernández Sánchez R, Pérez Pampín E, et al. CO22 use of Ixekizumab for psoriatic arthritis patients in real-world conditions. Value Health. 2022;25(12):S21.
doi: 10.1016/j.jval.2022.09.102
Murage MJ, Princic N, Park J, et al. Real-world treatment patterns and healthcare costs in patients with psoriatic arthritis treated with ixekizumab: a retrospective study. ACR Open Rheumatol. 2021;3(12):879–87.
doi: 10.1002/acr2.11347
pubmed: 34550647
pmcid: 8672175
Conesa-Nicolás E, García-Lagunar MH, Núñez-Bracamonte S, García-Simón MS, Mira-Sirvent MC. Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. Farm Hosp. 2020;45(1):16–21.
pubmed: 33443473